Zobrazeno 1 - 10
of 208
pro vyhledávání: '"Tarec Christoffer El Galaly"'
Autor:
Linda Aagaard Rasmussen, Peter Vedsted, Henry Jensen, Henrik Frederiksen, Tarec Christoffer El-Galaly, Ida Bruun Kristensen, Line Flytkjaer Virgilsen
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Multiple myeloma often presents with vague and non-specific symptoms. Many patients are diagnosed in unplanned rather than elective (planned) diagnostic pathways. This study investigates the diagnosis of multiple myeloma in unplan
Externí odkaz:
https://doaj.org/article/3b932bbcaf8d4666af6df463c7d6ae9c
Autor:
Jelena Jelicic, Karen Juul‐Jensen, Zoran Bukumiric, Mikkel Runason Simonsen, Michael Roost Clausen, Ahmed Ludvigsen Al‐Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Anne Ortved Gang, Peter Brown, Tarec Christoffer El‐Galaly, Thomas Stauffer Larsen
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background Several clinical prognostic models for diffuse large B‐cell lymphoma (DLBCL) have been proposed, including the most commonly used International Prognostic Index (IPI), the National Comprehensive Cancer Network IPI (NCCN‐IPI),
Externí odkaz:
https://doaj.org/article/962bda7300354816a5d7ddb24ee577af
Autor:
Jelena Jelicic, Karen Juul-Jensen, Zoran Bukumiric, Michael Roost Clausen, Ahmed Ludvigsen Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Peter Brown, Tarec Christoffer El-Galaly, Thomas Stauffer Larsen
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Currently, the International Prognostic Index (IPI) is the most used and reported model for prognostication in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). IPI-like variations have been proposed, but only a few have b
Externí odkaz:
https://doaj.org/article/8b627bc21d06479eb96599fd9fb6c239
Autor:
Srdan Verstovsek, Lynda Foltz, Vikas Gupta, Robert Hasserjian, Taghi Manshouri, John Mascarenhas, Ruben Mesa, Olga Pozdnyakova, Ellen Ritchie, Ivo Veletic, Katia Gamel, Habib Hamidi, Lyrialle Han, Brian Higgins, Kerstin Trunzer, Marianne Uguen, Dao Wang, Tarec Christoffer El-Galaly, Boyan Todorov, Jason Gotlib
Publikováno v:
Haematologica, Vol 108, Iss 10 (2023)
Pentraxin 2 (PTX-2; serum amyloid P component), a circulating endogenous regulator of the inflammatory response to tissue injury and fibrosis, is reduced in patients with myelofibrosis (MF). Zinpentraxin alfa (RO7490677, PRM-151) is a recombinant for
Externí odkaz:
https://doaj.org/article/853c9266e7f0447385d894bbf77cd11a
Autor:
Lale Kostakoglu, Federico Dalmasso, Paola Berchialla, Larry A. Pierce, Umberto Vitolo, Maurizio Martelli, Laurie H. Sehn, Marek Trněný, Tina G. Nielsen, Christopher R. Bolen, Deniz Sahin, Calvin Lee, Tarec Christoffer El‐Galaly, Federico Mattiello, Paul E. Kinahan, Stephane Chauvie
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 406-414 (2022)
Abstract Image texture analysis (radiomics) uses radiographic images to quantify characteristics that may identify tumour heterogeneity and associated patient outcomes. Using fluoro‐deoxy‐glucose positron emission tomography/computed tomography (
Externí odkaz:
https://doaj.org/article/b8bbe56c53944bd0a888cd8d151c81e5
Autor:
Tarec Christoffer El-Galaly, Verena I. Gaidzik, Mihnea-Alexandru Gaman, Darko Antic, Jessica Okosun, Mhairi Copland, Veronika Sexl, Adele K. Fielding, Robin Doeswijk, Helen Parker, Martin Dreyling, Konstanze Döhner, António Medina Almeida, Elizabeth Macintyre, John G. Gribben, Kirsten Grønbæk, on behalf of the EHA Diversity, Equity, and Inclusion Taskforce
Publikováno v:
HemaSphere, Vol 7, Iss 3, p e842 (2023)
Externí odkaz:
https://doaj.org/article/061eec178a40471bb4aebc1c6c453233
Autor:
Lasse Hjort Jakobsen, Andreas Kiesbye Øvlisen, Marianne Tang Severinsen, Joachim Bæch, Kristian Hay Kragholm, Ingrid Glimelius, Anne Ortved Gang, Judit Mészáros Jørgensen, Henrik Frederiksen, Christian Bjørn Poulsen, Michael Roost Clausen, Per Trøllund Pedersen, Robert Schou Pedersen, Christian Torp-Pedersen, Sandra Eloranta, Tarec Christoffer El-Galaly
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 1, Pp 1-7 (2022)
Abstract For most patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), R-CHOP immunochemotherapy leads to complete remission and 60–70% of patients remain progression-free after 5 years. Given a median age of 65, it is relevant to d
Externí odkaz:
https://doaj.org/article/bb7dc74d74fd4d8696aca7534432f57e
Autor:
Mia Sommer, Lene Kongsgaard Nielsen, Lars Børty Nielsen, Rasmus Froberg Brøndum, Marlene Maria Nielsen, Anne Stoffersen Rytter, Charles Vesteghem, Marianne Tang Severinsen, Tarec Christoffer El-Galaly, Martin Bøgsted, Mette Grønkjær, Lone Jørgensen
Publikováno v:
Health and Quality of Life Outcomes, Vol 19, Iss 1, Pp 1-11 (2021)
Abstract Background Patients with hematological cancer who experience relapse or progressive disease often face yet another line of treatment and continued mortality risk that could increase their physical and emotional trauma and worsen their health
Externí odkaz:
https://doaj.org/article/ce184fa0ab4249ae8ac6685488070625
Autor:
Marijana Nesic, Mads Sønderkær, Rasmus Froberg Brøndum, Tarec Christoffer El-Galaly, Inge Søkilde Pedersen, Martin Bøgsted, Karen Dybkær
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid neoplasm among adults,and approximately 30–40% of patients will experience relapse while 5–10% will suffer from primary refractory disease caused by different
Externí odkaz:
https://doaj.org/article/5d3004ebdec54d97874475d508d72aa5
Autor:
Mia Sommer, Lone Frandsen, Paw Jensen, Søren Ramme Nielsen, Lars Børty Nielsen, Rasmus Froberg Brøndum, Martin Bøgsted, Jakob Madsen, Marianne Tang Severinsen, Erik Elgaard Sørensen, Mette Grønkjær, Tarec Christoffer El-Galaly
Publikováno v:
BMC Health Services Research, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Patients with B-cell neoplasms in remission are monitored with regular physician visits at the hospital. The current standard follow-up procedure is not evidence-based or individualized to patient needs. To improve and individuali
Externí odkaz:
https://doaj.org/article/2e217e7856b14ae3bfdc0c26a826ed66